AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca roxadustat (evrenzo) — Emerging Markets YoY CER (%) (%)
Form 6-K / 20-F Product Sales Table
Latest, Q2 2026
-82.0%
Period ended Jun 30, 2026
Change on a year earlier
-64.0 pts
-18.0% in Q2 2025
History
18 quarters
Since Q1 2022
Sources
18
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Roxadustat (evrenzo) — Emerging Markets YoY CER (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | -82.0% | -64.0 pts | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | -47.0% | -51.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | -37.0% | -52.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | -18.0% | -44.0 pts | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | -18.0% | -44.0 pts | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 4.0% | -24.0 pts | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | 15.0% | -13.0 pts | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | 26.0% | -13.0 pts | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | 26.0% | -30.0 pts | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | 28.0% | -35.0 pts | Form 6-K FY2024Q1 Earnings Release ↗ |
| Q4 2023 | Dec 31, 2023 | 28.0% | -59.0 pts | Form 6-K FY2023Q4 Earnings Release ↗ |
| Q3 2023 | Sep 30, 2023 | 39.0% | +31.0 pts | Form 6-K FY2023Q3 Earnings Release ↗ |
| Q2 2023 | Jun 30, 2023 | 56.0% | +57.0 pts | Form 6-K FY2023Q2 Earnings Release ↗ |
| Q1 2023 | Mar 31, 2023 | 63.0% | +59.0 pts | Form 6-K FY2023Q1 Earnings Release ↗ |
| Q4 2022 | Dec 31, 2022 | 87.0% | – | Form 6-K FY2022Q4 Earnings Release ↗ |
| Q3 2022 | Sep 30, 2022 | 8.0% | – | Form 6-K FY2022Q3 Earnings Release ↗ |
| Q2 2022 | Jun 30, 2022 | -1.0% | – | Form 6-K FY2022Q2 Earnings Release ↗ |
| Q1 2022 | Mar 31, 2022 | 4.0% | – | Form 6-K FY2022Q1 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Roxadustat (evrenzo) — Emerging Markets YoY CER (%) (%), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_roxadustat_em_cer_yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.